Terah Crosson, APRN
Nurse Practitioner · Oklahoma City, OKNPI 1124687603
Payments from drug & device makers
Across 68 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$163
- AstraZeneca$140
- Myriad Genetic Laboratories, Inc.$114
- Genmab U.S., Inc.$96
- Gilead$95
- Merck$70
- plus $685 from 22 others
What the payments were for
- Food & beverage$1,26993%
- Education$957%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $163 |
| AstraZeneca | 7 | $140 |
| Myriad Genetic Laboratories, Inc. | 3 | $114 |
| Genmab U.S., Inc. | 5 | $96 |
| Gilead | 1 | $95 |
| Merck | 4 | $70 |
| Johnson & Johnson | 4 | $67 |
| Lilly USA, LLC | 3 | $65 |
| Eisai Inc. | 4 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $60 |
| Incyte Corporation | 3 | $54 |
| Genentech USA, Inc. | 2 | $36 |
| Dendreon Pharmaceuticals LLC | 2 | $36 |
| Pfizer | 2 | $34 |
| Novartis | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Morphosys, US Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Amgen | 1 | $13 |
How this compares
$1,364 in reported general payments places this provider in the 80th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 18 | $905 |
| Ondansetron OdtOndansetron | 19 | $372 |
| Prochlorperazine Maleate | 11 | $138 |
| Potassium Chloride | 14 | $65 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Oklahoma City
- Sara GoreOklahoma City$52K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Janelle WagnerOklahoma City$13K
- Stefanie RollinsOklahoma City$13K
- Lacey CampbellOklahoma City$13K
- Stacey Waggoner FisherOklahoma City$9K
- Karie StewartOklahoma City$9K
- Lori CraigOklahoma City$8K
- Jennifer LewisOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.